Glenmark Pharma, an India-based drug manufacturer that has been the focal point of a spate of recalls in recent years, has ...

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the acquisition and launch1 of Acetylcysteine Injection, 6 gm/30 mL ...

Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Polyethylene Glycol 3350, Powder for ...

Empagliflozin, which in addition to treating type-2 diabetes, also aids weight loss, and reduces cardiovascular and kidney ...

Glenmark launches Empagliflozin and combinations in India under Glempa brand, aiming to improve glycemic control and reduce ...

The recall affects around 14.76 lakh bottles of Atomoxetine Capsules in various strengths, produced by Glenmark ...

Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic ...

Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.

Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...

According to the U.S. health agency, Glenmark Pharmaceuticals is recalling over 15 lakh bottles of a generic drug used to ...

Glenmark Pharmaceuticals Inc, USA, an arm of the Mumbai-based Glenmark Pharmaceuticals, is recalling around 14.76 lakh ...

According to the company's statement, these medications are designed to improve glycemic control in adults with Type 2 Diabetes while also reducing cardiovascular outcomes in the patients.